Freeline Hemophilia B Gene Therapy May Have Advantage Over Competitors

Almost No Patients Required Post-Treatment Factor Replacement Therapy

 
• By Alaric DeArment
  
Hemophilia_525478450_1200.jpg
Freeline announced data from the Phase I/II study of its hemophilia B gene therapy. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Blood and Clotting

More from Therapeutic Category